Status:
UNKNOWN
The Effectiveness of Personalized Colorectal Cancer Screening Based on Fecal Hemoglobin Concentration
Lead Sponsor:
Esther Toes-Zoutendijk
Conditions:
Colorectal Cancer
Eligibility:
All Genders
56-71 years
Phase:
NA
Brief Summary
We aim to improve the yield and effectiveness of the Dutch colorectal cancer screening program by using a personalized screening strategy based on fecal Hemoglobin concentration in previous screening ...
Detailed Description
A fecal Hemoglobin concentration just below the cut-off of the fecal immunochemical test (FIT) is associated with a higher risk for the detection of colorectal cancer of advanced adenomas at consecuti...
Eligibility Criteria
Inclusion
- Previous negative FIT (below the cut-off of 47 microgram per gram feces)
Exclusion
- Previously tested with FIT cut-off of 15 microgram per gram feces
Key Trial Info
Start Date :
September 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
20000 Patients enrolled
Trial Details
Trial ID
NCT05423886
Start Date
September 1 2022
End Date
July 1 2025
Last Update
June 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ErasmusMC
Rotterdam, Netherlands, 3015 GD